Electric convulsive treatment is used for people suffering from major depression; however, not everybody is responsive to the treatment. ECT works 80% of the time but fails patients suffering from resistant-to-treatment depression 20% of the time along with side effects.
When ECT does not help, patients may feel further distress as they have invested their time, money and hopes in treatment and not received any desired results. Side effects after ECT can include seeing distressing visions or having nightmares, impaired memory, an increase in anxiety levels, and the depression is still there, no change.
ECT takes up much time; patients can take up to anything from 7 to 11 treatments to start seeing some improvement. ECT involves sending an electric current through the brain. The electrical current aims to get to work on the neurotransmitters that are responsible for emotions.
Some patients who have had the ECT treatment comment that the ECT treatment can make their depression worse and feel that it is not worth the time or investment if it fails to work make existing conditions such as anxiety, depression, and cognitive functions worse. The most common side effect is impaired memory of recent events.
ECT may not be suitable for those patients who have existing medical conditions such as cardiovascular illnesses. There is a risk of heart attack or heart interferences for those who have coronary heart disease. ECT was developed in the 1930s, and today there is still some stigma attached to the treatment. ECT, when it works, can take up to six weeks for the patient suffering from depression to see any noticeable effect.
In the past several decades, the focus has been shifted to another neurotransmitter glutamate. It was discovered that Esketamine has the most beneficial rapid results for treating patients who have suffered from major depression, including those patients who are regarded as resistant to treatment for major depression who have had electric shock treatment for their thoughts of suicide and major depression condition.
Esketamine is a faster and efficient acting antidepressant. It is believed to be a significant breakthrough in the treatment for those patients suffering from thoughts of suicide, self-harm, and major depression.
In major depression disorder cases, Esketamine has a significant response rate of 70% and a remission rate of 30% 24 hours after treatment and lasts for up to one week. Esketamine most likely improves the brain’s neural connectivity by boosting the plasticity in several locations in the brain, including the amygdala and hippocampus.
A brand new medication is available now for those patients who are treatment-resistant to other depression treatment. The European Commission has approved an intranasal spray developed by Jansen, a pharmaceutical company, to help end the depression cycle.
Highlights of the Intranasal Spray
- High central nervous system penetrance
- Ease of administration
- Esketamine contains fast-acting properties
- Contains anaesthetic, antidepressant, and pain reducing properties
- Works on the firstor second day upon using the intranasal spray
The new intranasal spray Spravato has many potentials and could potentially save the lives of those patients suffering from thoughts of suicide, self-harm acts, and major depression.
First launched in America and now available in our London clinic. This new nasal spray contains Esketamine, which works on the brain’s neurotransmitters, including glutamate. This new nasal spray Spravato helps to restore the brain’s connections. A safety study carried out monitoring the effects of the Esketamine spray has shown that Spravato can work from as early as the second day after treatment.
If you are sick and tired of feeling depressed and want fast results, please contact us for a free initial consultation.
NCI (2014, August 4) Molecular mechanism identified for activation and desensitisation of prominent neurotransmitter receptor in the brain. Retrieved from https://www.cancer.gov/news-events-/press-releases/2014/glutamatereceptors
Zarate, C Ionescu, D Niciu M (2013, December 8) Glutamate and its receptors in the pathophysiology and treatment of the major depressive disorder. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4048804/#dm139944332535696title
Johnson, C (2019, April 20) A Esketamine revolution for depression and pain? Spravato, fibromyalgia and ME/CFS. Retrieved from https://www.healthrising.org/blog/2019/04/20/Esketamine -fibromyalgia-spravato-esEsketamine -chronic-fatigue/
Popiolek K, Bejerot S, Brus O, Hammar A, Landen M, Lundberg J, Nordanskog P, Nordenskjoid (2019, July 23) Electroconvulsive therapy in bipolar depression – effectiveness and prognostic factors. Retrieved from https://onlinelibray.wiley.com/doi/full/10.1111/acps.13075
Tracy N, (2014, November 30) Bipolar Depression Treatment - - What to do if ECT Fails. Retrieved from https://www.healthyplace.com/blogs/breakingbipolar/2014/11/bipolar-depression-treatment-what-to-do-if-ect-fails
Purse M, (2020, March 22) How ECT is used for treating depression. Retrieved from https://www.verywellmind.com/ect-for-depression-and-anxiety-379903